AU2001294541A1 - Mammalian genes; related reagents and methods - Google Patents

Mammalian genes; related reagents and methods

Info

Publication number
AU2001294541A1
AU2001294541A1 AU2001294541A AU9454101A AU2001294541A1 AU 2001294541 A1 AU2001294541 A1 AU 2001294541A1 AU 2001294541 A AU2001294541 A AU 2001294541A AU 9454101 A AU9454101 A AU 9454101A AU 2001294541 A1 AU2001294541 A1 AU 2001294541A1
Authority
AU
Australia
Prior art keywords
methods
mammalian genes
related reagents
genes
reagents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294541A
Inventor
Naoko Arai
Daniel M. Gorman
Jeffery Grein
Hirokazu Kurata
Jeanine D. Mattson
Terrill K. Mcclanahan
Erin E. Murphy
Christi L. Parham
Theodore R. Sana
Chetan Savkoor
Kathleen M. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU2001294541A1 publication Critical patent/AU2001294541A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Nucleic acids encoding mammalian, e.g., primate or rodent, genes, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.
AU2001294541A 2000-09-08 2001-09-07 Mammalian genes; related reagents and methods Abandoned AU2001294541A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23126700P 2000-09-08 2000-09-08
US60/231,267 2000-09-08
PCT/US2001/028013 WO2002020569A2 (en) 2000-09-08 2001-09-07 Mammalian genes; related reagents and methods

Publications (1)

Publication Number Publication Date
AU2001294541A1 true AU2001294541A1 (en) 2002-03-22

Family

ID=22868480

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294541A Abandoned AU2001294541A1 (en) 2000-09-08 2001-09-07 Mammalian genes; related reagents and methods

Country Status (9)

Country Link
US (6) US7060800B2 (en)
EP (2) EP2298789B1 (en)
JP (2) JP2004509617A (en)
CN (1) CN1452633A (en)
AT (1) ATE549347T1 (en)
AU (1) AU2001294541A1 (en)
CA (1) CA2419979A1 (en)
MX (1) MXPA03002049A (en)
WO (1) WO2002020569A2 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2388019A1 (en) * 1999-11-05 2001-05-17 Human Genome Sciences, Inc. 24 human secreted proteins
WO2001040467A1 (en) 1999-12-03 2001-06-07 Zymogenetics, Inc. Human cytokine receptor
US20030170823A1 (en) 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
JP5015404B2 (en) 2000-08-08 2012-08-29 ザイモジェネティクス， インコーポレイテッド Soluble ZCYTOR11 cytokine receptor
US7358353B2 (en) 2000-08-22 2008-04-15 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
WO2002016593A2 (en) * 2000-08-22 2002-02-28 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
CA2419979A1 (en) * 2000-09-08 2002-03-14 Schering Corporation Mammalian genes; related reagents and methods
MXPA03004675A (en) * 2000-11-28 2003-09-05 Amgen Inc Transforming growth factor-beta-related molecules and uses thereof.
EP1356046B1 (en) * 2000-11-28 2009-10-14 ZymoGenetics, L.L.C. Cytokine receptor zcytor19
CA2439961A1 (en) 2001-03-27 2002-10-03 Zymogenetics, Inc. Human cytokine receptor
US7038032B2 (en) 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
US7910313B2 (en) 2001-04-20 2011-03-22 Zymogenetics, Inc. Cytokine protein family
EP1439223A1 (en) * 2001-10-02 2004-07-21 Mochida Pharmaceutical Co., Ltd. Novel class ii cytokine receptor
US7033787B2 (en) * 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
CA2480163A1 (en) 2002-03-22 2003-10-09 Zymogenetics, Inc. Anti-il-tif antibodies and methods of using in inflammation
JP4409962B2 (en) 2002-04-19 2010-02-03 ザイモジェネティクス，インコーポレイティド Cytokine receptor
US7141381B2 (en) 2002-04-25 2006-11-28 Bristol-Myers Squibb Company Human leucine-rich repeat-containing proteins specifically expressed in the nervous system
US7064107B2 (en) 2002-06-07 2006-06-20 Dyax Corp. Prevention and reduction of blood loss
WO2004037995A2 (en) 2002-10-23 2004-05-06 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29
DE10254601A1 (en) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
EP2343315A3 (en) * 2003-02-10 2011-11-23 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
JP2007525437A (en) 2003-03-24 2007-09-06 ザイモジェネティクス， インコーポレイテッド Anti-IL-20 antibodies and binding partners and methods for use in inflammation
EP1668031B1 (en) 2003-08-07 2008-03-12 ZymoGenetics, Inc. Homogeneous preparations of il-29
AU2004268145B2 (en) * 2003-08-29 2010-09-16 Takeda Pharmaceutical Company Limited Poly-PEGylated protease inhibitors
GB0325038D0 (en) 2003-10-27 2003-12-03 Ares Trading Sa Protein
US20050244423A1 (en) 2004-04-02 2005-11-03 Klucher Kevin M Methods for treating viral infection using IL-28 and IL-29 cysteine mutants
DE102004024617A1 (en) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
CN101829318B (en) 2004-07-29 2012-07-04 津莫吉尼蒂克斯有限责任公司 Use of IL-28 and IL-29 to treat cancer and autoimmune disorders
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
BRPI0516975A (en) 2004-10-22 2008-09-30 Zymogenetics Inc antibody or antigen-binding fragment thereof, pharmaceutical composition, immunoconjugate, hybridoma, monoclonal antibody, and use of an antibody or antigen-binding fragment thereof
GB0423973D0 (en) * 2004-10-28 2004-12-01 Ares Trading Sa C1q related points
JP2008539194A (en) * 2005-04-26 2008-11-13 ラボラトワール セローノ ソシエテ アノニム New treatment and / or prevention of cancer and / or arthritis
CA2616004A1 (en) 2005-07-20 2007-02-01 Zymogenetics, Inc. Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2008127975A2 (en) * 2007-04-11 2008-10-23 Alcon Research, Ltd. Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
BRPI0816837B1 (en) 2007-09-28 2022-10-18 Portola Pharmaceuticals, Inc PHARMACEUTICAL COMPOSITIONS, ISOLATED TWO-CHAIN POLYPEPTIDE AND USE OF A PHARMACEUTICAL COMPOSITION
EP2414517B1 (en) 2009-03-30 2016-09-21 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
US9056106B2 (en) 2009-07-15 2015-06-16 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same
WO2011041640A1 (en) * 2009-10-01 2011-04-07 Alcon Research, Ltd. Olopatadine compositions and uses thereof
US8609355B2 (en) 2011-07-26 2013-12-17 Indicator Systems International, Inc. Assays for the detection of microbes
EP3626254A1 (en) 2012-03-16 2020-03-25 University Health Network Soluble toso protein and its use in treating autoimmune disorders
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
SG11201501286PA (en) 2012-08-23 2015-05-28 Agensys Inc Antibody drug conjugates (adc) that bind to 158p1d7 proteins
RU2678127C2 (en) 2012-11-13 2019-01-23 Бионтех Аг Agents for treatment of claudin expressing cancer diseases
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
KR20160127817A (en) 2014-03-07 2016-11-04 유니버시티 헬스 네트워크 Methods and compositions for modifying the immune response
KR102555955B1 (en) 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 Compositions and methods for treatment of diabetic macular edema
US10287338B2 (en) 2015-07-10 2019-05-14 Miran NERSISSIAN Factor VIII protein compositions and methods of treating of hemophilia A
WO2017023863A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
US11564982B2 (en) 2017-01-04 2023-01-31 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
EP3565834A1 (en) 2017-01-04 2019-11-13 The Research Institute at Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
EP3595445A1 (en) 2017-03-15 2020-01-22 The Research Institute at Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
CN110229226B (en) * 2019-05-23 2023-04-11 西安医学院 SLFN11 truncated peptide and application and pharmaceutical composition thereof
AU2020311897A1 (en) 2019-07-08 2022-02-03 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US88426A (en) 1869-03-30 Improved velocipede
US2736896A (en) 1951-12-04 1956-02-28 Sperry Rand Corp Horn antenna system
DE2031216A1 (en) 1969-06-19 1971-01-14 Citizen Watch Co Ltd , Tokio Day and date setting device for clocks with calendar
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4859609A (en) 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
CA2419979A1 (en) * 2000-09-08 2002-03-14 Schering Corporation Mammalian genes; related reagents and methods
US11068393B2 (en) 2019-10-17 2021-07-20 Microsoft Technology Licensing, Llc Enhanced concurrency garbage collection stack scanning

Also Published As

Publication number Publication date
US7696317B2 (en) 2010-04-13
CN1452633A (en) 2003-10-29
US20110165165A1 (en) 2011-07-07
WO2002020569A2 (en) 2002-03-14
US20100104576A1 (en) 2010-04-29
JP2004509617A (en) 2004-04-02
US8148507B2 (en) 2012-04-03
MXPA03002049A (en) 2003-07-24
US8426573B2 (en) 2013-04-23
EP1315743B1 (en) 2012-11-07
US20020142292A1 (en) 2002-10-03
JP2009039124A (en) 2009-02-26
US7893211B2 (en) 2011-02-22
ATE549347T1 (en) 2012-03-15
US20090155242A1 (en) 2009-06-18
US7427668B2 (en) 2008-09-23
WO2002020569A3 (en) 2003-01-23
EP1315743A2 (en) 2003-06-04
EP2298789A1 (en) 2011-03-23
US20050186620A1 (en) 2005-08-25
CA2419979A1 (en) 2002-03-14
US20120164147A1 (en) 2012-06-28
EP2298789B1 (en) 2012-03-14
US7060800B2 (en) 2006-06-13

Similar Documents

Publication Publication Date Title
AU2001294541A1 (en) Mammalian genes; related reagents and methods
AU6135101A (en) Mammalian receptor proteins; related reagents and methods
ZA200604026B (en) IL-23 and its receptor ; related reagents and methods
WO2001090358A3 (en) Mammalian receptor proteins; related reagents and methods
CY1109093T1 (en) Mammalian Receptor Proteins, Related Reagents, and Related Methods
EP2305715A3 (en) Monoclonal antibody to osteoprotegerin binding protein
WO2001090151A3 (en) Human receptor proteins; related reagents and methods
WO2001036467A3 (en) Mammalian receptor proteins; related reagents and methods
WO2002068646A3 (en) Mammalian cytokines; receptors; related reagents and methods
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
NZ515382A (en) OX2 receptor homologs
WO2005065711A3 (en) Mammalian receptor proteins; related reagents and methods
WO2000017363A3 (en) Interleukin-1 like molecule: interleukin-1-zeta; nucleic acids, polypeptides, antibodies, their uses
WO1999019480A3 (en) Human receptor proteins; related reagents and methods
WO2003022992A3 (en) Mammalian genes; related reagents
WO2002063009A8 (en) Lp mammalian proteins; related reagents
WO2001046419A3 (en) Mammalian prion proteins; related reagents and methods
CY1114280T1 (en) ANTI-COMPETITIVE ANTI-COMPETITIVE ANTI-COMPETITIVE COMPETITORS OR THEIR RELIGIONS